[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "29.2 times protection from vaccination", "description": "SARS-CoV-2 Infections and Hospitalizations Among Persons Aged \u226516 Years, by Vaccination Status \u2014 Los Angeles County, California, May 1\u2013July 25, 2021\n\nhttps://www.cdc.gov/mmwr/volumes/70/wr/mm7034e5.htm?s_cid=mm7034e5_w\n\nA proportion of fully vaccinated persons will become infected\n\nLos Angeles County Department of Public Health\n\nMay 1 to July 25, 2021\n\nAmong 43,127 infections\n\n10,895 (25.3%) fully vaccinated\n\n1,431 (3.3%) partially vaccinated\n\n30,801 (71.4%) unvaccinated\n\nHospitalized / ITU / Ventilated in those infected\n\nFully vaccinated\n\n3.2%, 0.5% 0.2%\n\nPartially vaccinated\n\n6.2%, 1.0%, 0.3%\n\nUnvaccinated\n\n7.6%, 1.5%, 0.5%\n\np less than 0.001 for all comparisons\n\nJuly 25, fully vaccinated versus unvaccinated\n\nInfection rate among unvaccinated, x 4.9\n\nHospitalization rate in unvaccinated, x 29.2\n\nMay testing\n\nDifferences in median Ct values by vaccination status\n\nJuly testing\n\nNo differences were detected among specimens from fully vaccinated\n\nThese infection and hospitalization rate data indicate that authorized vaccines were protective against SARS-CoV-2 infection and severe COVID-19 during a period when transmission of the Delta variant was increasing\n\nUS hospital pressures\n\nhttps://www.forbes.com/sites/joewalsh/2021/08/19/these-6-states-have-almost-no-icu-beds-left-as-covid-hospitalizations-soar/?sh=ad819756bb58\n\nNationally, ITU capacity at 78%\n\none-third with covid (or 22,345)\n\nAlabama, more ICU patients than total beds\n\nDozens forced to wait for space\n\nGeorgia, 94% of statewide ICU beds are full\n\nFlorida and Mississippi, 93%\n\nTexas, 92.7%\n\nKentucky, 90.7%\n\nLouisiana, 89.3%\n\nMissouri 88.9%\n\nFollowed by Oklahoma (87.9%), Arkansas (87.4%), Nevada (85.4%), North Carolina (84.8%), \nSouth Carolina (83.8%), New Mexico (83.6%), Idaho (82.7%) Maine (80.4%)\n\nUK, ONS\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nW / E 14 August 2021\n\nAntibodies, 94.2%\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyantibodyandvaccinationdatafortheuk/latest\n\nPercentage of the community population that had COVID-19 was: \n\n1.28% in England (1 in 80 people)\n\n0.77% in Wales (1 in 130 people) \n\n1.92% in Northern Ireland (1 in 50 people) \n\n0.49% in Scotland (1 in 200 people) \n\nAn estimated 1.46% of the UK population were experiencing self-reported long COVID 4th in July 2021\n\n945,000 people in private households (1.46%)\n\n4 in 10 were experiencing these symptoms over a year\n\nSymptoms adversely affected the day-to-day activities of around two-thirds\n\nFatigue, shortness of breath, muscle ache, loss of smell, GI\n\nMore common in \n\nfemales\n\nthose aged 35 to 69 years\n\npeople living in the most deprived areas\n\nthose working in health or social care\n\nthose with another health condition or disability.\n\n4th July to 14th August, percentage of people testing positive daily\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections\n\nDeaths, W/E 13th August\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/latest\n\n14.1% above the five-year average (1,203 more deaths)\n\nEngland and Wales, 571 mentioned \u201cnovel coronavirus (COVID-19)\u201d\n\n(5.5% of all deaths)\n\nNorth Korea\n\nPopulation, 25 million\n\nhttps://www.washingtonpost.com/world/asia_pacific/north-korea-vaccine-delay/2021/08/24/fdf1b054-031a-11ec-825d-01701f9ded64_story.html\n\nVaccinations so far, 0\n\nUN now offering doses, Covax \n\n3 million doses of Sinovac\n\nTechnical issues still need to be resolved\n\nSealed its borders to trade and visitors\n\nEssentially no international staff on the ground\n\nFloods, typhoons, heat wave\n\nLag in routine vaccination program since 2020\n\n2007 measles vaccine campaign, 3.3 million people per day", "link": "https://www.youtube.com/watch?v=2vYslhtMbDw", "date_published": "2021-08-26 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Questions for FDA", "description": "Peter Doshi, senior editor, The BMJ\n\nThe FDA should demand adequate, controlled studies with long term follow up, and make data publicly available, before granting full approval to covid-19 vaccines\n\nhttps://blogs.bmj.com/bmj/2021/08/23/does-the-fda-think-these-data-justify-the-first-full-approval-of-a-covid-19-vaccine/\n\nPfizer press release, 1 April, 2021\n\nhttps://investors.pfizer.com/investor-news/press-release-details/2021/Pfizer-and-BioNTech-Confirm-High-Efficacy-and-No-Serious-Safety-Concerns-Through-Up-to-Six-Months-Following-Second-Dose-in-Updated-Topline-Analysis-of-Landmark-COVID-19-Vaccine-Study/default.aspx\n\nBNT162b2 is highly effective with 91.3% vaccine efficacy\n\nData cut-off date was 13 March\n\nmeasured seven days through up to six months after the second dose\n\nSix Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine, (Published 28 July)\n\nhttps://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1\n\nOngoing phase 3 covid-19 vaccine trial\n\nVE against COVID-19 was 91% (95% CI 89.0-93.2) through up to 6 months of follow-up, \n\nThe current report provides updated efficacy analyses conducted on cases accrued up to March 13, 2021.\n\nEfficacy, an average decline of ~6% every 2 months\n\nFDA Approves First COVID-19 Vaccine, (23rd August)\n\nhttps://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine\n\nBased on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease.\n\nNew COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status \u2014 New York, May 3\u2013July 25, 202, (Published 18th August)\n\nhttps://www.cdc.gov/mmwr/volumes/70/wr/mm7034e1.htm?s_cid=mm7034e1_w\n\n(NY data)\n\nProtection against infection\n\nJuly 25, 79.8%\n\nAge adjusted effectiveness against hospitalizations\n\nJuly 25, 91.9% to 95.3%\n\nDuring May 3\u2013July 25, 2021, the overall age-adjusted VE against new COVID-19 cases for all adults declined from 91.7% to 79.8%. \n\nDuring the same period, the overall age-adjusted VE against hospitalization was relatively stable, ranging from 91.9% to 95.3%.\n\nIsrael sees drop in Pfizer vaccine protection against infections\n\nhttps://www.reuters.com/world/middle-east/israel-sees-drop-pfizer-vaccine-protection-against-infections-still-strong-2021-07-05/\n\nVaccine effectiveness in preventing both infection and symptomatic disease fell to 64% since June 6\n\nIsrael says Pfizer Covid vaccine is just 39% effective as delta spreads, but still prevents severe illness\n\nhttps://www.cnbc.com/2021/07/23/delta-variant-pfizer-covid-vaccine-39percent-effective-in-israel-prevents-severe-illness.html\n\nData from June 20 and July 17\n\nPfizer sales\n\nhttps://www.bmj.com/content/374/bmj.n2096\n\nhttps://www.fiercepharma.com/pharma/pfizer-now-expects-covid-19-vaccine-sales-33-5b-a-7-5b-increase-from-3-months-ago\n\nThe company now predicts 2021 sales of $33.5 billion\n\nPfizer and BioNTech now expect to deliver 2.1 billion doses of Comirnaty worldwide this year and manufacture 3 billion. \n\n(at average price of $15.95)\n\n2022 production capacity at 4 billion doses", "link": "https://www.youtube.com/watch?v=WOtvpk9rZLs", "date_published": "2021-08-25 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]